Skip to main content

Table 2 Univariate analysis of factors affecting survival.

From: Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

Factor Category Event Median OS 95% CI p value
Age (years) <58 44 6.7 m 6.0 - 7.4 0.41
  ≥58 47 6.2 m 3.2 - 9.3  
Gender Male 67 6.6 m 5.7 - 7.5 0.83
  Female 24 6.4 m 2.5 - 10.4  
ECOG PS 0/1 54 7.2 m 6.0 - 8.4 <0.01
  2/3 33 4.5 m 3.3 - 5.7  
  NA 4 2.6 m 0.0 - 6.9  
Primary site Duodenum 71 6.2 m 5.0 - 7.5 <0.01
  Jejunoileum 20 11.9 m 5.1 - 18.6  
Histology WD/MD 44 6.8 m 6.2 - 7.3 0.45
  Undifferentiated 38 5.1 m 2.3 - 7.9  
  Undetermined 9 8.3 m 0.1 - 16.6  
Initial status Recurrent 17 10.5 m 4.0 - 17.1 0.21
  Locally advanced 4 6.8 m 5.9 - 7.8  
  Metastatic 70 5.8 m 4.3 - 7.4  
Primary tumor Resected 29 11.8 m 3.8 - 19.8 <0.01
  Still present 62 5.2 m 3.5 - 6.8  
Number of metastasis 0 4 6.8 m 5.9 - 7.8 0.20
  1 50 7.1 m 5.8 - 8.4  
  ≥2 37 5.5 m 2.7 - 8.3  
Liver metastasis Yes 39 4.2 m 3.6 - 4.8 <0.01
  No 52 7.8 m 6.3 - 9.3  
Peritoneal metastasis Yes 42 5.9 m 3.7 - 8.0 0.03
  No 49 8.6 m 5.5 - 11.8  
IALN metastasis Yes 41 5.5 m 3.6 - 7.4 <0.01
  No 50 7.7 m 6.8 - 8.6  
Lung metastasis Yes 6 3.1 m 0.0 - 6.9 0.14
  No 85 6.7 m 5.6 - 7.8  
Bone metastasis Yes 3 5.2 m 2.4 - 7.9 0.75
  No 88 6.6 m 5.7 - 7.5  
Chemotherapy (+) 40 11.8 m 4.6 - 19.0 <0.01
  (-) 51 4.1 m 3.1 - 5.1  
  1. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; NA, not available; WD, well-differentiated; MD, moderately differentiated; IALN, intra-abdominal lymph node.